MiNK Therapeutics (INKT) Profit After Tax (2020 - 2026)

MiNK Therapeutics has reported Profit After Tax for 7 years, with the latest figure at -$2.7 million in Q1 2026.

• Quarterly Profit After Tax rose 0.9% year-over-year to -$2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.4 million (down 29.82% YoY) and the FY2025 annual result came in at -$12.5 million, down 15.85% from the prior year.
• Profit After Tax eased to -$2.7 million in Q1 2026 per INKT's latest filing, from -$2.5 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$1.9 million in Q3 2024 and troughed at -$8.0 million in Q4 2022.
• A 5-year average of -$4.6 million and a median of -$4.2 million in 2025 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax tumbled 102.2% in 2022, then soared 62.84% in 2024.
• Over 5 years, Profit After Tax stood at -$8.0 million in 2022, then soared by 31.89% to -$5.4 million in 2023, then jumped by 59.15% to -$2.2 million in 2024, then slipped by 14.4% to -$2.5 million in 2025, then dropped by 7.9% to -$2.7 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$2.7 million, -$2.5 million, and -$2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.